Lecanemab
Lecanemab is a pharmaceutical drug with 12 clinical trials. Currently 8 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
8
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
Cognitive Neurology Unit Clinical Registry
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Clinical Trials (12)
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
Cognitive Neurology Unit Clinical Registry
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Feasibility of Lecanemab Registry and Clinical Outcome Measures
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
A Study of Subcutaneous Lecanemab in Healthy Participants
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12